Category - Developments


Oramed Pharma issues letter to shareholders

In a letter to shareholders, Nadav Kidron, CEO of Oramed Pharmaceuticals (NASDAQ:ORMP), detailed the company’s recent achievements and future milestones. “2015 was a very significant year for us at Oramed, setting the...


Can-Fite submits Phase 3 protocol for RA study

Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has submitted its Phase 3 clinical study protocol to the Institutional Review Board of Barzilai Medical Center in Israel and will file similar submissions in several...

BioLight Life Sciences Ltd.

Canada clears BioLight’s IOPtiMate system

The Canadian Medical Devices Bureau has approved BioLight Life Sciences Investments’ (OTCQX:BLGTY; TASE:BOLT) IOPtiMate system for the treatment of glaucoma, allowing the company to commercialize the surgical system in...


Can-Fite gets patent in Japan for CF101

The Japan Patent Office has granted Can-Fite BioPharma (NYSE MKT:CANF) (TASE:CFBI) a patent for its lead drug candidate, CF101, for the reduction of intraocular pressure (IOP). CF101 is an A3 adenosine receptor (A3AR)...

Titan Pharmaceuticals Logo

FDA panel to review NDA for Probuphine

The FDA’s Psychopharmacologic Drugs Advisory Committee has scheduled a meeting on Jan. 12 to review the NDA for Titan Pharmaceuticals’ (NASDAQ: TTNP) Probuphine for the maintenance treatment of opioid addiction. The FDA...